Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Virpax Pharmaceuticals Inc
(NQ:
VRPX
)
1.510
-0.160 (-9.58%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 25, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Virpax Pharmaceuticals Inc
< Previous
1
2
3
Next >
Virpax® Successfully Completes Preclinical Dermal Safety Studies for Epoladerm™
January 18, 2022
From
Virpax Pharmaceuticals, Inc.
Via
Business Wire
Virpax® Pharmaceuticals to Present at H.C. Wainwright BioConnect Virtual Conference
January 04, 2022
From
Virpax® Pharmaceuticals, Inc.
Via
Business Wire
Virpax Pharmaceuticals Recaps Milestones and Highlights Product Portfolio
December 28, 2021
From
Virpax Pharmaceuticals, Inc.
Via
Business Wire
Virpax Announces Clinical Trial Site in Canada for First in Human Study of Epoladerm™ for Pain Associated with Osteoarthritis of the Knee
December 20, 2021
From
Virpax Pharmaceuticals, Inc.
Via
Business Wire
Virpax Reports Successful Results of Toxicology and Pharmacokinetic Study for Epoladerm™
December 08, 2021
From
Virpax Pharmaceuticals, Inc.
Via
Business Wire
Virpax Pharmaceuticals Reports 2021 Third Quarter Results and Recent Developments
November 15, 2021
From
Virpax Pharmaceuticals, Inc.
Via
Business Wire
Virpax Advances Envelta™ Development with NCATS Under CRADA Agreement
November 10, 2021
From
Virpax Pharmaceuticals, Inc.
Via
Business Wire
Virpax Signs Agreement with Sinclair Research to Initiate Investigational New Drug (IND)-Enabling Studies for AnQlar™
October 06, 2021
From
Virpax Pharmaceuticals Inc.
Via
Business Wire
Virpax to Present at the NobleCon Online Pain Management Investor Forum on Channelchek.com on October 7, 2021
October 01, 2021
From
Virpax Pharmaceuticals, Inc.
Via
Business Wire
Virpax to Develop Intranasal Cannabidiol Product for the Management of Epilepsy in Adults and Children
September 20, 2021
From
Virpax Pharmaceuticals, Inc.
Via
Business Wire
Virpax® Pharmaceuticals Announces Closing of $40 Million Public Offering of Common Stock
September 16, 2021
From
Virpax Pharmaceuticals Inc.
Via
Business Wire
Virpax® Pharmaceuticals Announces Pricing of $40 Million Public Offering of Common Stock
September 14, 2021
From
Virpax Pharmaceuticals Inc.
Via
Business Wire
Virpax Pharmaceuticals Announces Poster Presentation for Envelta™ at PAINWeek 2021
September 02, 2021
From
Virpax Pharmaceuticals
Via
Business Wire
Virpax Announces MMS019 Manufacturing and Supply Agreement
August 26, 2021
From
Virpax® Pharmaceuticals, Inc.
Via
Business Wire
Virpax® Pharmaceuticals Receives FDA Response and Guidance on MMS019
August 17, 2021
From
Virpax® Pharmaceuticals, Inc.
Via
Business Wire
Virpax Pharmaceuticals Reports 2021 Second Quarter Results and Recent Developments
August 10, 2021
From
Virpax Pharmaceuticals, Inc.
Via
Business Wire
Virpax® Pharmaceuticals Strengthens Board of Directors with the Appointment of Gerald W. Bruce and Michael F. Dubin, CPA to its Board
July 30, 2021
From
Virpax Pharmaceuticals
Via
Business Wire
Virpax Pharmaceuticals Provides Progress Update on Product Candidates
July 07, 2021
From
Virpax Pharmaceuticals Inc.
Via
Business Wire
Virpax to Use Envelta™ IND Enabling Study Results for Two Additional Indications
June 21, 2021
From
Virpax Pharmaceuticals
Via
Business Wire
Virpax Pharmaceuticals to Present at LD Micro Invitational XI Event on Wednesday, June 9th at 4:30 PM ET
June 02, 2021
From
Virpax Pharmaceuticals, Inc.
Via
Business Wire
Virpax Pharmaceuticals Reports 2021 First Quarter Results and Recent Developments
May 18, 2021
From
Virpax Pharmaceuticals, Inc.
Via
Business Wire
Virpax Pharmaceuticals Engages Torreya Capital to Advise on Global Partnering Efforts
April 22, 2021
From
Virpax Pharmaceuticals, Inc.
Via
Business Wire
Virpax’s MMS019 Reduced Nasal and Brain Viral Load in Animal Study
April 19, 2021
From
Virpax Pharmaceuticals, Inc.
Via
Business Wire
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.